Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-10-31T09:42:58.422Z Has data issue: false hasContentIssue false

The low FODMAP diet in clinical practice: where are we and what are the long-term considerations?

Published online by Cambridge University Press:  07 July 2023

Miranda C. E. Lomer*
Affiliation:
Department of Nutrition and Dietetics, Guy's and St Thomas’ NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK Department of Nutritional Sciences, King's College London, Stamford Street, London, UK
*
Corresponding author: Miranda C. E. Lomer, Email miranda.lomer@kcl.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

A diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) improves functional bowel symptoms and is a second-line dietary management strategy for the treatment of irritable bowel syndrome (IBS). The diet is complex and involves three stages: restriction, reintroduction and personalisation and clinical effectiveness is achieved with dietitian-led education; however, this is not always available. The aim of this review is to provide an update on the evidence for using the low FODMAP diet, with a focus on the impact of FODMAP restriction and reintroduction considering long-term management of IBS in a clinical setting. Randomised controlled trials have assessed symptom response, quality of life, dietary intake and changes to the gut microbiota during FODMAP restriction. Systematic reviews and meta-analyses consistently report that FODMAP restriction has a better symptom response compared with control diets and a network analysis reports the low FODMAP diet is superior to other dietary treatments for IBS. Research focused on FODMAP reintroduction and personalisation is limited and of lower quality, however common dietary triggers include wheat, onion, garlic, pulses and milk. Dietitian-led delivery of the low FODMAP diet is not always available and alternative education delivery methods, e.g. webinars, apps and leaflets, are available but remove the personalised approach and may be less acceptable to patients and may introduce safety concerns in terms of nutritional adequacy. Predicting response to the low FODMAP diet using symptom severity or a biomarker is of great interest. More evidence on less restrictive approaches and non-dietitian-led education delivery methods are needed.

Type
Conference on ‘Architecture of food: Processing, structure and health’
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of The Nutrition Society

Irritable bowel syndrome (IBS) is a disorder of the gut–brain interaction(Reference Drossman and Hasler1) more commonly known as a functional bowel disorder and is characterised by recurrent abdominal pain associated with a change in bowel habits(Reference Mearin, Lacy and Chang2). Disordered bowel habits include diarrhoea and/or constipation and are often associated with other symptoms such as abdominal bloating, flatulence and borborygmi(Reference Mearin, Lacy and Chang2). Subtypes include diarrhoea-predominant IBS with loose stools at least 25 % of the time, constipation-predominant IBS with hard/lumpy stools at least 25 % of the time, mixed type IBS where both loose and hard/lumpy stools occur at least 25 % of the time for each and unclassified IBS where both loose and hard/lumpy stools occur less than 25 % of the time(Reference Mearin, Lacy and Chang2).

The aetiopathogenesis of IBS is complex involving psychological and biological factors which include changes in visceral sensitivity, gut motility, stress, the gut-brain axis, immune activation, gut microbiota and having a genetic predisposition(Reference Drossman and Hasler1).

IBS is extremely debilitating and negatively impacts health-related quality of life (QoL) with individual quotes such as ‘I can't leave the house in fear of not finding a toilet’ and ‘I avoid eating when I go out to prevent needing to run to the loo’. It occurs in 4–12 % of the population depending on diagnostic criteria and country, more often in people under 50 years of age and approximately 70 % of people affected are women(Reference Lovell and Ford3). A positive diagnosis for IBS is made using a targeted approach with detailed medical history of symptoms, examination and some simple blood (e.g. full blood count, coeliac antibodies, inflammatory markers) and stool tests (e.g. faecal calprotectin) to rule out organic causes of symptoms(4,Reference Vasant, Paine and Black5) . Direct UK costs are £90–£316/patient/year, while annual projections are £45⋅6–£200 million(Reference Canavan, West and Card6). Ideally, IBS should be managed in primary care, however it accounts for up to 50 % of secondary care referrals to gastroenterology(Reference Canavan, West and Card6,Reference Soubieres, Wilson and Poullis7) .

Management takes a holistic approach and considers pharmacology, diet and lifestyle and psychological strategies(4,Reference Vasant, Paine and Black5,Reference McKenzie, Bowyer and Leach8) . First-line British Dietetic Association (BDA) and National Institute for Health and Care Excellence (NICE)(4) dietary advice, known as traditional dietary advice, involves guidance on healthy eating; reducing dietary fat, caffeine and alcohol where they are symptom triggers and ensuring the diet is adequate in dietary fibre while encouraging dietary diversity. In addition, checking for the presence of lactose intolerance and providing information on suitable low lactose alternatives is key. Eating lifestyle and eating patterns should be assessed and if chaotic or erratic, ideas to improve these will be discussed(4,Reference McKenzie, Bowyer and Leach8) . Probiotics may also be considered as there is evidence that they provide some symptom benefit(Reference McKenzie, Thompson and Gulia9). A diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) or the low FODMAP diet is a second-line management strategy and recommended in guidelines from the UK(4,Reference Vasant, Paine and Black5,Reference McKenzie, Bowyer and Leach8) and internationally(Reference Chey, Hashash and Manning10,Reference Linedale and Andrews11) . The low FODMAP diet is a relatively new treatment option and the first study published in 2008 was a double-blind, randomised, placebo-controlled rechallenge trial of fructans and fructose in patients with IBS who had responded to a low FODMAP diet(Reference Shepherd, Parker and Muir12). The diet is complex and involves three stages: restriction, reintroduction and personalisation and clinical effectiveness is achieved with dietitian-led education; however, this is not always available. The aim of this review is to provide an update on the evidence for using the low FODMAP diet, with a focus on the impact of FODMAP restriction and reintroduction considering long-term management of IBS in a clinical setting.

What are FODMAP and why do they induce gastrointestinal symptoms?

The oligosaccharides include fructans (e.g. wheat, onion, garlic) and galacto-oligosaccharides (e.g. beans and pulses). They are poorly digested in the human gut and are readily fermented by the colonic microbiota(Reference Shepherd, Lomer and Gibson13,Reference Staudacher, Irving and Lomer14) . The disaccharide is lactose, which is only a FODMAP in individuals with lactose malabsorption. The monosaccharide is fructose in excess of glucose (e.g. honey, mango) and malabsorption is thought to arise from a defect in one or more of the facilitated fructose transport pathways (e.g. GLUT 2 or GLUT 5) in the small intestine(Reference Jones, Butler and Brooks15). The polyols are sugar alcohols and include sorbitol (e.g. stone fruit) and mannitol (e.g. some mushrooms). Polyol absorption is passive and predominantly occurs in the jejunum and varies hugely between individuals(Reference Shepherd, Lomer and Gibson13,Reference Staudacher, Irving and Lomer14,Reference Staudacher and Whelan16) .

MRI has been used to visualise the gastrointestinal tract and demonstrates that FODMAP increase small intestinal water (e.g. free-fructose) and colonic gas (e.g. fructans) in healthy individuals and people with IBS(Reference Major, Pritchard and Murray17,Reference Murray, Wilkinson-Smith and Hoad18) . Some FODMAP, e.g. fructans and galacto-oligosaccharides are malabsorbed in everyone, however it is only people with gut hypersensitivity, e.g. people with IBS, who develop gastrointestinal symptoms. The vagus nerve connects the enteric nervous system and the central nervous system, which is often referred to as the gut–brain axis. Recent mechanistic work looking at pain receptors in the brain show that fructans increase signalling in the pain-related areas of the brain supporting the theory that IBS is a dysfunction of the gut–brain axis(Reference Wu, Masuy and Biesiekierski19).

Briefly, the low FODMAP diet incorporates three stages: FODMAP restriction which involves restricting foods containing FODMAP for a period of 4–8 weeks; FODMAP reintroduction which details challenging with high FODMAP foods one by one to identify which foods induce symptoms; FODMAP personalisation which involves incorporating high FODMAP foods back into the diet to tolerance while continuing to avoid those foods identified as dietary triggers during FODMAP reintroduction.

FODMAP restriction

FODMAP restriction is where foods high in FODMAP are restricted alongside advice on inclusion of suitable low FODMAP alternative foods to ensure the diet is nutritionally adequate in energy, macro- and micronutrients. It is good practice for patients to be given detailed information on the mechanisms of how FODMAP induce symptoms to enable them to understand the reasons for such a complex dietary protocol. Detailed resources on foods to include and exclude, with recipe ideas, meal plans are all part of the education package(Reference Whelan, Martin and Staudacher20).

Prior to starting a low FODMAP diet, it is important to carry out a detailed assessment of past medical history, weight history, diet and symptoms to ensure a low FODMAP diet is appropriate. Contraindications to the low FODMAP diet include an inability to understand and apply the complexities of the diet, an already overly restricted diet, unexplained weight loss or low BMI, an eating disorder including avoidant restrictive food intake disorder or orthorexia nervosa and constipation-predominant symptoms(Reference Whelan, Martin and Staudacher20Reference Sultan, Varney and Halmos23). For any of these contraindications, a modified approach may be required or an alternative treatment plan.

Research suggests that FODMAP restriction achieves symptom control within 2–4 weeks(Reference Whelan, Martin and Staudacher20,Reference Black, Staudacher and Ford24) ; however, in clinical practice reviewing patients before 4 weeks is rarely encountered due to clinical capacity and high demands on dietetic services. Thus, FODMAP restriction is often followed for 4–8 weeks. The clinical effectiveness of the restriction stage of the low FODMAP has been assessed in more than 15 randomised controlled trials. Two recent systematic reviews and meta-analyses and a systematic review and network meta-analysis support the use of the low FODMAP diet(Reference Black, Staudacher and Ford24Reference Wang, Yang and Zhang26). Van Lanen et al. from the Netherlands included twelve studies in their meta-analysis. All studies compared the low FODMAP diet to a control diet, nine were parallel trials and three were cross-over trials. The meta-analysis reported that FODMAP restriction for between 4 d and 3 months reduced the severity of IBS by a moderate to large extent when compared with a control diet(Reference van Lanen, de Bree and Greyling25). Furthermore, the authors report improvements in IBS quality of life (IBS-QoL)(Reference Patrick, Drossman and Frederick27) following FODMAP restriction in six studies when compared with a control diet(Reference van Lanen, de Bree and Greyling25,Reference van Lanen, de Bree and Greyling28) . Wang et al. from China included ten studies in their systematic review and meta-analyses also found that FODMAP restriction had greater global improvement of symptoms compared to a control diet in seven studies but for IBS-QoL there was no difference in five studies. They also assessed anxiety and depression using the hospital anxiety and depression scale(Reference Zigmond and Snaith29) which was reported in only two studies but there were no differences found between the low FODMAP diet and a control diet(Reference Wang, Yang and Zhang26). A systematic review and network meta-analysis from the UK and Australia assessed the efficacy of the low FODMAP diet in relation to the efficacy of other dietary treatments(Reference Black, Staudacher and Ford24). The authors report on a network meta-analysis of thirteen randomised controlled trials, and with a probability of 99 %, they showed that a low FODMAP diet was more efficacious than any other comparator diet, including first-line BDA/NICE guidelines for global IBS symptoms, abdominal pain and bloating(Reference Black, Staudacher and Ford24).

Universal FODMAP restriction should not be a long-term strategy due to negative impacts on nutrient intake and microbial diversity with continuing avoidance of high FODMAP foods(Reference Whelan, Martin and Staudacher20,Reference Tuck and Barrett30) . Some FODMAP are prebiotics and have a positive effect on the gastrointestinal microbiota, so a reduction in their intake during FODMAP restriction has the potential to negatively impact the gastrointestinal microbiota(Reference So, Loughman and Staudacher31). A systematic review on the colonic microbiome following FODMAP restriction reports that from nine studies there is a consistent reduction in the abundance of Bifidobacteria (Reference So, Loughman and Staudacher31). There were no other consistent negative impacts on microbial diversity or faecal SCFA.

A reduction in FODMAP intake can potentially impair nutrient intake, e.g. some sources of fructans are fortified with folic acid, B vitamins and iron (wheat starch, bread, breakfast cereals) and sources of lactose provide calcium in a readily bioavailable form (milk and milk products)(Reference Lomer, Parkes and Sanderson32). Furthermore, many high FODMAP foods provide dietary fibre from a diverse range of fruit, vegetables and grains. Dietitian-led education provides patients with personalised advice on suitable alternatives to high FODMAP foods during FODMAP restriction and research indicates that macronutrient and dietary fibre intakes are largely unaffected(Reference Staudacher, Ralph and Irving33). However, FODMAP restriction does reduce diet quality and many nutrients do not meet dietary recommendations(Reference Staudacher, Ralph and Irving33). Thus, to ensure the low FODMAP diet is safe as well as effective, FODMAP reintroduction to tolerance and personalisation of the diet is key to management.

FODMAP reintroduction and personalisation

Most of the research on the clinical effectiveness of the low FODMAP diet has been carried out during FODMAP restriction; however, FODMAP reintroduction and FODMAP personalisation are important stages of the diet. FODMAP reintroduction is where dietary triggers can be identified using high FODMAP food challenges. FODMAP personalisation is where the diet becomes more personalised for long-term application to encourage dietary diversity to meet nutrient recommendations and restore any negative impacts to the gut microbiome resulting from FODMAP restriction. Having a better understanding of dietary triggers enables patients to take control of symptom management, giving them autonomy and an increased feeling of self-management in clinical decision making for the long term.

FODMAP reintroduction uses high FODMAP food challenges with increasing amounts of a specific food over a 3 d period(Reference Whelan, Martin and Staudacher20). In clinical practice, usually one food from each FODMAP group is challenged with to test for tolerance to that FODMAP, e.g. for lactose, milk may be used for the food challenge with day 1 containing approximately 4 g lactose (i.e. 125 ml), and amounts on day 2 and day 3 being double (250 ml) and triple (375 ml) the amount for day 1, respectively. An exclusion to this rule is for advice on fructans, and challenging with several foods is suggested (e.g. wheat, rye, onion, garlic) due to their differing degrees of polymerisation which leads to differences in colonic bacterial fermentation and gas production(Reference Probert and Gibson34). Different protocols for FODMAP reintroduction are available in different countries with constant amounts of challenge foods across the 3 challenge days(Reference Tuck and Barrett30) or 4 d to challenge(Reference Bellini, Tonarelli and Barracca35) and differing durations for washout in between challenges depending on whether symptoms occur during the challenge(Reference Whelan, Martin and Staudacher20,Reference Tuck and Barrett30,Reference Bellini, Tonarelli and Barracca35,Reference Singh, Tuck and Gibson36) . Several studies have used double-blinded powdered FODMAP challenges to identify which FODMAP are symptom triggers(Reference Shepherd, Parker and Muir12,Reference Cox, Prince and Myers37,Reference Van den Houte, Colomier and Mari38) ; however, the food matrix and combining FODMAP-containing foods in meals may be important in determining tolerance thresholds in the clinical setting.

Where education on FODMAP restriction, reintroduction and personalisation is provided, long-term symptom response has been observed in 57–67 % of patients(Reference O'Keeffe, Jansen and Martin39,Reference Staudacher, Rossi and Kaminski40) and up to 83 % reported >50-point reduction in IBS symptom severity scale(Reference Bellini, Tonarelli and Barracca35,Reference Francis, Morris and Whorwell41) . In addition, other studies assessing symptoms for FODMAP restriction and reintroduction according to local protocol show symptom reduction between 55 and 89 %(Reference de Roest, Dobbs and Chapman42Reference Weynants, Goossens and Genetello44) lower symptom scores, e.g. using the gastrointestinal symptom rating scale(Reference Svedlund, Sjodin and Dotevall45) or symptom response(Reference Svedlund, Sjodin and Dotevall45Reference Seamark, Barclay and Marchant51) (Table 1). Improvements in QoL using short form 36 health survey questionnaire(Reference Brazier, Harper and Jones52) or IBS-QoL(Reference Patrick, Drossman and Frederick27) have also been reported(Reference Staudacher, Rossi and Kaminski40,Reference Harvie, Chisholm and Bisanz47,Reference Goyal, Batta and Nohria49) . Furthermore, nutritional adequacy of the diet and FODMAP intake returns to levels observed in baseline habitual diets and food-related QoL improves compared with baseline(Reference Bellini, Tonarelli and Barracca35,Reference Staudacher, Rossi and Kaminski40) . In addition, diet acceptability, food-related QoL, healthcare utilisation and work absenteeism do not negatively impact patients after FODMAP personalisation compared with patients who returned to a habitual diet(Reference O'Keeffe, Jansen and Martin39).

Table 1. Studies in patients with IBS measuring long-term outcomes following low FODMAP restriction, reintroduction and personalisation according to local protocol

IBS, irritable bowel syndrome; IBS-D, diarrhoea-predominant IBS; GSRS, gastrointestinal symptom rating scale(Reference Svedlund, Sjodin and Dotevall45); IBS-SSS, IBS symptom severity scale(Reference Francis, Morris and Whorwell41); IBS-QoL, IBS quality of life(Reference Patrick, Drossman and Frederick27); QoL, quality of life; HADS, hospital anxiety and depression scale(Reference Zigmond and Snaith29); SF-36, short-form 36 health survey questionnaire(Reference Brazier, Harper and Jones52); FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides and polyols.

In the long term, the negative impact on luminal Bifidobacteria levels seen after FODMAP restriction(Reference So, Loughman and Staudacher31) are restored following FODMAP personalisation(Reference Staudacher, Rossi and Kaminski40) supporting the importance of the reintroduction and personalisation stages of the low FODMAP diet.

There are a small number of studies that have researched which foods are identified as dietary triggers during FODMAP reintroduction. A prospective study 6–18 months after low FODMAP education showed that IBS patients who had followed the three-stage low FODMAP diet protocol had lower intakes of onion, garlic and wheat pasta and higher intakes of gluten-free bread, lactose-free/plant-based alternatives to milk and milk products and low FODMAP vegetables when compared with IBS patients who had reportedly returned to their habitual diet after FODMAP restriction(Reference O'Keeffe, Jansen and Martin39). Another study reports on limited concordance between perceived dietary triggers before and after the low FODMAP diet(Reference Bellini, Tonarelli and Barracca35). The authors report that lactose is the only FODMAP with moderate agreement suggesting that it is important to carry out FODMAP challenges to confirm which foods really are dietary triggers. In a very small study of eight patients with IBS who completed FODMAP reintroduction, common foods identified as triggers were wheat and rye bread, pasta, sweetheart cabbage, onion, garlic, leek, broccoli, green peas, cauliflower, kidney beans, chickpeas, sweet potatoes, avocado, mushrooms, apples and apple juice(Reference Ankersen, Weimers and Bennedsen48). Dietary triggers have also been reported for 2053 users of a low FODMAP diet mobile application with the top dietary triggers and foods challenged being wheat bread, onion, garlic, milk and wheat pasta. For any given food challenge, less than half of users reported the food as a dietary trigger(Reference Dimidi, Whelan and Lomer53). This is an important finding and indicates that more than half the time, FODMAP challenges do not induce symptoms. Therefore, foods that are tolerated can be reintroduced back into the diet for long-term self-management reducing safety concerns regarding the negative impact of FODMAP restriction on the gut microbiota and nutritional adequacy.

Application to clinical practice

Patients with IBS referred for dietary advice to manage functional bowel symptoms can be triaged to ascertain their suitability for education on the low FODMAP diet(Reference Whelan, Martin and Staudacher20). The triage process includes a detailed clinical, symptom and dietary assessment to ensure that a low FODMAP diet is an appropriate treatment option considering past medical history, current symptom profile and any dietary issues related to eating lifestyle, diet diversity and dietary restrictions. The optimal delivery of low FODMAP education is dietitian-led(Reference O'Keeffe and Lomer54). First, this enables patients to receive personalised and detailed advice on suitable low FODMAP alternative foods to replace high FODMAP foods during FODMAP restriction which assists with dietary diversity and nutritional adequacy and ensures dietary fibre intake is adequate for optimal stool frequency and consistency. Secondly, patients are provided with structured information on FODMAP reintroduction and personalisation which is rarely considered without the support of a dietitian(Reference Tuck, Reed and Muir43,Reference Trott, Aziz and Rej55) . Thirdly, patients are supported with personalised high-quality information improving their confidence in the material which helps to apply the diet in a real-world situation. However, the success of dietitian-led education for the low FODMAP diet has led to an overwhelming increase in dietetic referrals, causing a bottleneck in the clinical pathway due to limited supply in the dietetic workforce resulting in longer waiting lists for treatment(Reference Tuck, Reed and Muir43,Reference Trott, Aziz and Rej55) . To overcome this challenge, different delivery methods from dietitian-led group education, other healthcare professional delivery, mobile applications or leaflets have all been considered(Reference Sultan, Varney and Halmos23,Reference Trott, Aziz and Rej55Reference Dimidi, Whelan and Lomer57) .

Dietitian-led group education on the low FODMAP diet is clinically effective, increases clinical capacity and reduces costs in the clinical pathway(Reference Whigham, Joyce and Harper56,Reference Chan, Zarate-Lopez and Martin58) . It is not suitable for every patient and careful triage will identify which patients will benefit from this approach and who will need a one-to-one approach, e.g. patients with complex dietary needs, current or previous eating disorders, language barriers or atypical symptoms. Although group education may reduce the personalised approach to some extent, it provides patients with peer support and evidence supports the use of groups up to twelve patients(Reference Whigham, Joyce and Harper56).

Some general practitioners and gastroenterologists have limited dietetic access for IBS referrals and thus provide patients with basic written information, e.g. food lists, or suggest they search the internet for information without guidance on reputable websites(Reference Trott, Aziz and Rej55). Although patients trust their general practitioner and gastroenterologists, they can be concerned about the validity and simplicity of information they receive, furthermore such information may not align with healthy eating guidelines(Reference Trott, Aziz and Rej55). Patients also find that non-dietitian led advice does not enable them to deal with social situations around preparing and eating meals and eating out with family and friends(Reference Trott, Aziz and Rej55).

The use of mobile apps in healthcare is rapidly growing(Reference Ankersen, Weimers and Burisch59) and there are apps dedicated to the low FODMAP diet to support users. Some apps provide detailed information on portion sizes of suitable and unsuitable foods, recipe ideas and meal planning while others enable users to monitor symptoms during the different stages of the diet and identify dietary triggers(Reference Dimidi, Whelan and Lomer53,Reference Varney, Barrett and Scarlata60) .

Patient webinars on first-line dietary advice for IBS were developed by a group of dietitians in primary care to provide non-dietitian led education as part of the clinical pathway(Reference Williams, Barclay and Harper61). Patients found the webinars an acceptable alternative to dietetic appointments, and this reduced dietetic referrals for IBS by 44 %. Almost a third of patients who took part in the webinar survey said they were keen to watch a webinar on the low FODMAP diet, so the group developed this and it has been viewed by thousands of people(Reference Williams, Barclay and Harper61).

A feasibility study assessed whether leaflets or an app could be used to educate patients on the low FODMAP diet rather than dietitian-led education. The leaflets were comprehensive booklets providing information on the mechanisms of FODMAP and where they occur in the diet along with detailed lists of suitable and unsuitable foods, meal plans including information on avoidance of constipation, low FODMAP plant-based protein, low FODMAP recipes, lists of suitable food products and detailed information on FODMAP reintroduction and personalisation(Reference Dimidi, Whelan and Lomer57). The app described the three stages of the low FODMAP diet with videos to support users on using the apps functions, i.e. providing users information to search for suitable and unsuitable foods using the integral camera function to scan food barcodes for suitability as well as providing lists of suitable and unsuitable foods(Reference Dimidi, Whelan and Lomer53). Acceptability of the different delivery methods was measured; the leaflets were considered inferior to the app or dietitian-led education and did not provide enough information for participants to self-manage without further support. There were improvements in symptom severity for all types of education methods although the study was not powered to detect this.

A service evaluation in primary care showed that dietitian-led education on the low FODMAP led to significant symptom improvement which was maintained at least 11 months after the initial treatment(Reference Seamark, Barclay and Marchant51). In addition, after dietitian-led education, there were significant reductions in general practitioner and gastroenterologist appointments related to symptoms when compared with the previous 12 months suggesting that low FODMAP education may improve self-management and reduce the burden of clinical follow-up. Furthermore, patients reported less medication use and investigations for gut symptoms.

Since the Covid-19 pandemic, there has been a rapid shift in delivery of care from face-to-face to virtual telephone and video clinics(Reference Gilbert, Billany and Adam62,Reference Rej, Sanders and Shaw63) which generally are acceptable to patients and clinicians. Virtual clinics provide a more sustainable option for healthcare and increases patient choice; however, digitalisation of services can be costly when considering information governance and the correct digital infrastructure, information technology, hardware and software that need to be integrated into clinical pathways. Many patients find virtual clinics more acceptable than face-to-face clinics citing convenience and less environmental impact(Reference Gilbert, Billany and Adam62). Furthermore, changes in healthcare delivery are likely to generate long-term cost savings for healthcare providers and improve sustainability.

A low FODMAP diet is considered as a ‘top-down’ approach to management and a modified approach or ‘bottom-up’ may be considered more appropriate for some people(Reference Halmos and Gibson22). Indeed, a randomised trial comparing a low FODMAP diet, a gluten-free diet and a BDA/NICE first-line advice diet in ninety-nine patients with non-constipated IBS reported similar improvements in symptom severity across the three diets; however, the BDA/NICE first-line advice was reported as being cheaper and more convenient than the other two diets(Reference Rej, Sanders and Shaw63). The low FODMAP diet certainly had a greater number of patients reporting improved symptom severity compared with the other two groups, but the authors report that the study was underpowered to detect this. It would be of interest to establish whether a modified approach to the low FODMAP diet, i.e. a less restrictive version would be as clinically effective and more acceptable to patients to follow.

Eating disorders such as avoidant restrictive food intake disorder or orthorexia nervosa are not uncommon in IBS(Reference Hunt, Dalvie and Ipek64) and when patients with IBS are suspected of having an eating disorder, they are more often likely to restrict their diet rather than have body dysmorphia(Reference Sultan, Varney and Halmos23). These patients need a comprehensive assessment to determine whether FODMAP restriction would be appropriate as their diet may already be limited and nutritionally inadequate. Furthermore, a strategy to lessen the dietary restrictions is often considered appropriate in the clinical setting and further supports using an FODMAP light approach to management(Reference Sultan, Varney and Halmos23,Reference Gibson, Halmos and So65,Reference Scarlata, Catsos and Smith66) .

Due to the complexity of the low FODMAP diet and knowing that approximately a third of people with IBS will be non-responders, it is pertinent to identify whether a certain symptom profile or a biomarker can predict response. One study has assessed symptom severity for predicting response to a low FODMAP diet and reported that high symptom severity scores using the IBS symptom severity scale at baseline led to a greater response to a low FODMAP diet(Reference Algera, Demir and Tornblom67). However, other studies using metagenomics have assessed whether there are biomarkers that can predict response. One study in adults with IBS suggests that having a certain faecal bacterial profile might predict non-response to a low FODMAP diet but not to BDA/NICE first-line advice(Reference Bennet, Bohn and Storsrud68). Another study in children with IBS reported that those who responded to a low FODMAP diet had microbiomes with greater saccharolytic metabolic capacity at baseline, i.e. those able to ferment complex carbohydrates such as inulin which is an FODMAP(Reference Chumpitazi, Cope and Hollister69). Both studies report on the abundance of bacterial taxa but have opposing results with reference to prediction of response to a low FODMAP diet, indicating a need for further investigation in a more heterogeneous population. A further study identified a greater clinical response to the low FODMAP diet in patients with IBS who had a distinct pathogenic-like gut microbiota at baseline compared to those who had a more health-like gut microbiota(Reference Vervier, Moss and Kumar70). Finally, faecal volatile organic compound profiles have been used as a measure of microbial functionality and volatile organic compound profiles at baseline that contained fifteen specific features were able to predict response in IBS patients with a high degree of accuracy, specificity and sensitivity for the low FODMAP diet(Reference Rossi, Aggio and Staudacher71). These preliminary research studies in small sample sizes are of great interest, external validation in heterogeneous populations is needed to develop biomarkers that can be used cheaply and quickly in the clinical setting.

Dietary exclusion leading to symptom response followed by food rechallenge to confirm symptom induction is the gold standard for identification of food intolerance and is the principle behind the low FODMAP diet(Reference Lomer72). Hydrogen and/or methane breath tests can be used to identify lactose malabsorption and whether there is a need to restrict lactose, but breath testing is not useful for other FODMAP due to a lack of reproducibility(Reference Whelan, Martin and Staudacher20,Reference Yao, Tuck and Barrett73) . Confocal laser endomicroscopy has been considered as a measure of direct food intolerance as it can visualise changes in the gut mucosa in response to food antigens; however, it is an invasive and expensive procedure and research suggests it is not sensitive or specific enough for widespread use(Reference Bojarski, Tangermann and Barmeyer74).

In conclusion, a low FODMAP diet improves functional bowel symptoms and is a second-line dietary management strategy for patients with IBS. The restriction stage of the low FODMAP diet is superior to other dietary treatments for IBS and achieves symptom response, improves QoL but negatively impacts the abundance of gut Bifidobacteria and diet quality; however, FODMAP reintroduction and personalisation are important stages of the low FODMAP diet, maintaining symptom response and restoring nutrient adequacy and the gut microbiota. Dietitian-led delivery of the low FODMAP diet is optimal but not always available and alternative education delivery methods, e.g. webinars, apps and leaflets, are available and should include FODMAP reintroduction and personalisation to mitigate any safety issues. It should be noted that these delivery methods remove the personalised approach and may be less acceptable to patients. Predicting response to the low FODMAP diet using symptom severity or a biomarker is of great interest. More evidence on less restrictive approaches and non-dietitian-led education delivery methods is needed.

Financial Support

None.

Conflict of Interest

M. C. E. L. was a co-inventor of a mobile application described in this review and was a co-applicant of a research grant from Clasado Biosciences Ltd.

Authorship

M. C. E. L. developed, wrote and edited the final manuscript.

References

Drossman, DA & Hasler, WL (2016) Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology 150, 12571261.CrossRefGoogle ScholarPubMed
Mearin, F, Lacy, BE, Chang, L et al. (2016) Bowel disorders. Gastroenterology 150, 13931407.Google Scholar
Lovell, RM & Ford, AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10, 712721, e4.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence (NICE) (2017) Irritable bowel syndrome in adults: diagnosis and management clinical guideline [CG61]. https://www.nice.org.uk/guidance/cg61 (accessed 11/02/2023).Google Scholar
Vasant, DH, Paine, PA, Black, CJ et al. (2021) British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 70, 12141240.CrossRefGoogle ScholarPubMed
Canavan, C, West, J & Card, T (2014) Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 40, 10231034.CrossRefGoogle ScholarPubMed
Soubieres, A, Wilson, P, Poullis, A et al. (2015) Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service. Frontline Gastroenterol 6, 246251.CrossRefGoogle Scholar
McKenzie, YA, Bowyer, RK, Leach, H et al. (2016) British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 29, 549575.CrossRefGoogle ScholarPubMed
McKenzie, YA, Thompson, J, Gulia, P et al. (2016) British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 29, 576592.CrossRefGoogle ScholarPubMed
Chey, WD, Hashash, JG, Manning, L et al. (2022) AGA clinical practice update on the role of diet in irritable bowel syndrome: expert review. Gastroenterology 162, 17371745, e5.CrossRefGoogle ScholarPubMed
Linedale, EC & Andrews, JM (2017) Diagnosis and management of irritable bowel syndrome: a guide for the generalist. Med J Aust 207, 309315.CrossRefGoogle ScholarPubMed
Shepherd, SJ, Parker, FC, Muir, JG et al. (2008) Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 6, 765771.CrossRefGoogle ScholarPubMed
Shepherd, SJ, Lomer, MC & Gibson, PR (2013) Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 108, 707717.CrossRefGoogle ScholarPubMed
Staudacher, HM, Irving, PM, Lomer, MC et al. (2014) Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 11, 256266.CrossRefGoogle ScholarPubMed
Jones, HF, Butler, RN & Brooks, DA (2011) Intestinal fructose transport and malabsorption in humans. Am J Physiol Gastrointest Liver Physiol 300, G202G206.CrossRefGoogle ScholarPubMed
Staudacher, HM & Whelan, K (2017) The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut 66, 15171527.CrossRefGoogle ScholarPubMed
Major, G, Pritchard, S, Murray, K et al. (2017) Colon hypersensitivity to distension, rather than excessive gas production, produces carbohydrate-related symptoms in individuals with irritable bowel syndrome. Gastroenterol 152, 124133, e2.CrossRefGoogle ScholarPubMed
Murray, K, Wilkinson-Smith, V, Hoad, C et al. (2014) Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 109, 110119.CrossRefGoogle ScholarPubMed
Wu, J, Masuy, I, Biesiekierski, JR et al. (2022) Gut-brain axis dysfunction underlies FODMAP-induced symptom generation in irritable bowel syndrome. Aliment Pharmacol Ther 55, 670682.CrossRefGoogle ScholarPubMed
Whelan, K, Martin, LD, Staudacher, HM et al. (2018) The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet 31, 239255.CrossRefGoogle ScholarPubMed
Bellini, M, Tonarelli, S, Nagy, AG et al. (2020) Low FODMAP diet: evidence, doubts, and hopes. Nutrients 12, 148; doi:10.3390/nu12010148.CrossRefGoogle ScholarPubMed
Halmos, EP & Gibson, PR (2019) Controversies and reality of the FODMAP diet for patients with irritable bowel syndrome. J Gastroenterol Hepatol 34, 11341142.CrossRefGoogle ScholarPubMed
Sultan, N, Varney, JE, Halmos, EP et al. (2022) How to implement the 3-phase FODMAP diet into gastroenterological practice. J Neurogastroenterol Motil 28, 343356.CrossRefGoogle ScholarPubMed
Black, CJ, Staudacher, HM & Ford, AC (2022) Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut 71, 11171126.CrossRefGoogle ScholarPubMed
van Lanen, AS, de Bree, A & Greyling, A (2021) Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr 60, 35053522.CrossRefGoogle ScholarPubMed
Wang, J, Yang, P, Zhang, L et al. (2021) A low-FODMAP diet improves the global symptoms and bowel habits of adult IBS patients: a systematic review and meta-analysis. Front Nutr 8, 683191.CrossRefGoogle ScholarPubMed
Patrick, DL, Drossman, DA, Frederick, IO et al. (1998) Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 43, 400411.CrossRefGoogle ScholarPubMed
van Lanen, AS, de Bree, A & Greyling, A (2021) Correction to: efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr 60, 3523.CrossRefGoogle ScholarPubMed
Zigmond, AS & Snaith, RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67, 361370.CrossRefGoogle ScholarPubMed
Tuck, C & Barrett, J (2017) Re-challenging FODMAPs: the low FODMAP diet phase two. J Gastroenterol Hepatol 32(Suppl. 1), 1115.CrossRefGoogle ScholarPubMed
So, D, Loughman, A & Staudacher, HM (2022) Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. Am J Clin Nutr 116, 943952.CrossRefGoogle ScholarPubMed
Lomer, MC, Parkes, GC & Sanderson, JD (2008) Review article: lactose intolerance in clinical practice – myths and realities. Aliment Pharmacol Ther 27, 93103.CrossRefGoogle ScholarPubMed
Staudacher, HM, Ralph, FSE, Irving, PM et al. (2020) Nutrient intake, diet quality, and diet diversity in irritable bowel syndrome and the impact of the low FODMAP diet. J Acad Nutr Diet 120, 535547.CrossRefGoogle ScholarPubMed
Probert, HM & Gibson, GR (2002) Investigating the prebiotic and gas-generating effects of selected carbohydrates on the human colonic microflora. Lett Appl Microbiol 35, 473480.CrossRefGoogle ScholarPubMed
Bellini, M, Tonarelli, S, Barracca, F et al. (2020) A low-FODMAP diet for irritable bowel syndrome: some answers to the doubts from a long-term follow-up. Nutrients 12, 2360; doi:10.3390/nu12082360.CrossRefGoogle Scholar
Singh, P, Tuck, C, Gibson, PR et al. (2022) The role of food in the treatment of bowel disorders: focus on irritable bowel syndrome and functional constipation. Am J Gastroenterol 117, 947957.CrossRefGoogle ScholarPubMed
Cox, SR, Prince, AC, Myers, CE et al. (2017) Fermentable carbohydrates [FODMAPs] exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial. J Crohns Colitis 11, 14201429.CrossRefGoogle ScholarPubMed
Van den Houte, K, Colomier, E, Mari, Z et al. (2021) Efficacy of a new approach to the reintroduction phase of the low-FODMAP diet in IBS. Gastroenterology 160, S76SS7.CrossRefGoogle Scholar
O'Keeffe, M, Jansen, C, Martin, L et al. (2018) Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil 30, e13154. https://doi.org/10.1111/nmo.13154.CrossRefGoogle ScholarPubMed
Staudacher, HM, Rossi, M, Kaminski, T et al. (2022) Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol Motil 34, e14241.CrossRefGoogle ScholarPubMed
Francis, CY, Morris, J & Whorwell, PJ (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11, 395402.CrossRefGoogle ScholarPubMed
de Roest, RH, Dobbs, BR, Chapman, BA et al. (2013) The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. Int J Clin Pract 67, 895903.CrossRefGoogle ScholarPubMed
Tuck, CJ, Reed, DE, Muir, JG et al. (2020) Implementation of the low FODMAP diet in functional gastrointestinal symptoms: a real-world experience. Neurogastroenterol Motil 32, e13730.CrossRefGoogle ScholarPubMed
Weynants, A, Goossens, L, Genetello, M et al. (2020) The long-term effect and adherence of a low fermentable oligosaccharides disaccharides monosaccharides and polyols (FODMAP) diet in patients with irritable bowel syndrome. J Hum Nutr Diet 33, 159169.CrossRefGoogle ScholarPubMed
Svedlund, J, Sjodin, I & Dotevall, G (1988) GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33, 129134.CrossRefGoogle ScholarPubMed
Gravina, AG, Dallio, M, Romeo, M et al. (2020) Adherence and effects derived from FODMAP diet on irritable bowel syndrome: a real life evaluation of a large follow-up observation. Nutrients 12, 928; doi:10.3390/nu12040928.CrossRefGoogle ScholarPubMed
Harvie, RM, Chisholm, AW, Bisanz, JE et al. (2017) Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. World J Gastroenterol 23, 46324643.CrossRefGoogle ScholarPubMed
Ankersen, DV, Weimers, P, Bennedsen, M et al. (2021) Long-term effects of a web-based low-FODMAP diet versus probiotic treatment for irritable bowel syndrome, including shotgun analyses of microbiota: randomized, double-crossover clinical trial. J Med Internet Res 23, e30291.CrossRefGoogle ScholarPubMed
Goyal, O, Batta, S, Nohria, S et al. (2021) Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea-predominant irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol Hepatol 36, 21072115.CrossRefGoogle ScholarPubMed
Maagaard, L, Ankersen, DV, Vegh, Z et al. (2016) Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J Gastroenterol 22, 40094019.CrossRefGoogle ScholarPubMed
Seamark, L, Barclay, Y, Marchant, C et al. (2021) Long-term symptom severity in people with irritable bowel syndrome following dietetic treatment in primary care: a service evaluation. J Hum Nutr Diet 34, 890900.CrossRefGoogle ScholarPubMed
Brazier, JE, Harper, R, Jones, NM et al. (1992) Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br Med J 305, 160164.CrossRefGoogle ScholarPubMed
Dimidi, E, Whelan, K & Lomer, MCE (2020) FODMAP-specific mobile application: impact on gut symptoms in 11,689 people, and dietary triggers in 2,053 people. Proc Nutr Soc 79, E8.CrossRefGoogle Scholar
O'Keeffe, M & Lomer, MC (2017) Who should deliver the low FODMAP diet and what educational methods are optimal: a review. J Gastroenterol Hepatol 32(Suppl. 1), 2326.CrossRefGoogle ScholarPubMed
Trott, N, Aziz, I, Rej, A et al. (2019) How patients with IBS use low FODMAP dietary information provided by general practitioners and gastroenterologists: a qualitative study. Nutrients 11, 1313; doi:10.3390/nu11061313.CrossRefGoogle ScholarPubMed
Whigham, L, Joyce, T, Harper, G et al. (2015) Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. J Hum Nutr Diet 28, 687696.CrossRefGoogle ScholarPubMed
Dimidi, E, Whelan, K & Lomer, MCE (2020) Investigating optimal education regarding the low FODMAP diet in functional bowel disorders: a feasibility randomised controlled trial of leaflet vs mobile application vs dietetic consultation. Proc Nutr Soc 79, E7.CrossRefGoogle Scholar
Chan, MMH, Zarate-Lopez, N & Martin, L (2022) Group education on the low FODMAP diet improves gastrointestinal symptoms but neither anxiety or depression in irritable bowel syndrome. J Hum Nutr Diet 35, 425434.CrossRefGoogle ScholarPubMed
Ankersen, DV, Weimers, P & Burisch, J (2017) Whats ‘App-ening’: the help of new technologies in nutrition in digestive diseases. Curr Opin Clin Nutr Metab Care 20, 426431.CrossRefGoogle ScholarPubMed
Varney, J, Barrett, J, Scarlata, K et al. (2017) FODMAPs: food composition, defining cutoff values and international application. J Gastroenterol Hepatol 32(Suppl. 1), 5361.CrossRefGoogle ScholarPubMed
Williams, M, Barclay, Y, Harper, L et al. (2020) Feasibility, acceptability and cost efficiency of using webinars to deliver first-line patient education for people with irritable bowel syndrome as part of a dietetic-led gastroenterology service in primary care. J Hum Nutr Diet 33, 758766.CrossRefGoogle ScholarPubMed
Gilbert, AW, Billany, JCT, Adam, R et al. (2020) Rapid implementation of virtual clinics due to COVID-19: report and early evaluation of a quality improvement initiative. BMJ Open Qual 9, e000985. doi:10.1136/bmjoq-2020-000985.CrossRefGoogle ScholarPubMed
Rej, A, Sanders, DS, Shaw, CC et al. (2022) Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the low FODMAP diet, and the gluten-free diet. Clin Gastroenterol Hepatol 20, 28762887, e15.CrossRefGoogle ScholarPubMed
Hunt, MG, Dalvie, A, Ipek, S et al. (2022) Acceptability and efficacy of the Zemedy app versus a relaxation training and meditation app for IBS: protocol for a randomised controlled trial. BMJ Open 12, e055014.CrossRefGoogle ScholarPubMed
Gibson, PR, Halmos, EP, So, D et al. (2022) Diet as a therapeutic tool in chronic gastrointestinal disorders: lessons from the FODMAP journey. J Gastroenterol Hepatol 37, 644652.CrossRefGoogle ScholarPubMed
Scarlata, K, Catsos, P & Smith, J (2020) From a dietitian's perspective, diets for irritable bowel syndrome are not one size fits all. Clin Gastroenterol Hepatol 18, 543545.CrossRefGoogle Scholar
Algera, JP, Demir, D, Tornblom, H et al. (2022) Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: a randomized crossover trial. Clin Nutr 41, 27922800.CrossRefGoogle ScholarPubMed
Bennet, SMP, Bohn, L, Storsrud, S et al. (2018) Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut 67, 872881.CrossRefGoogle ScholarPubMed
Chumpitazi, BP, Cope, JL, Hollister, EB et al. (2015) Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 42, 418427.CrossRefGoogle ScholarPubMed
Vervier, K, Moss, S, Kumar, N et al. (2022) Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut 71, 18211830.CrossRefGoogle ScholarPubMed
Rossi, M, Aggio, R, Staudacher, HM et al. (2018) Volatile organic compounds in feces associate with response to dietary intervention in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 16, 385391, e1.CrossRefGoogle ScholarPubMed
Lomer, MC (2015) Review article: the aetiology, diagnosis, mechanisms and clinical evidence for food intolerance. Aliment Pharmacol Ther 41, 262275.CrossRefGoogle ScholarPubMed
Yao, CK, Tuck, CJ, Barrett, JS et al. (2017) Poor reproducibility of breath hydrogen testing: implications for its application in functional bowel disorders. United European Gastroenterol J 5, 284292.CrossRefGoogle ScholarPubMed
Bojarski, C, Tangermann, P, Barmeyer, C et al. (2022) Prospective, double-blind diagnostic multicentre study of confocal laser endomicroscopy for wheat sensitivity in patients with irritable bowel syndrome. Gut 71, 15671576.CrossRefGoogle ScholarPubMed
Moon, SJ, Lee, WY, Hwang, JS et al. (2017) Accuracy of a screening tool for medication adherence: a systematic review and meta-analysis of the Morisky medication adherence scale-8. PLoS ONE 12, e0187139.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Studies in patients with IBS measuring long-term outcomes following low FODMAP restriction, reintroduction and personalisation according to local protocol